PDF(Pubmed)
Abstract：
Acute viral pharyngitis (AVP) is a common respiratory illness affecting many individuals. Despite symptomatic treatment management of AVP, therapies are lacking to target a broad spectrum of viruses and the inflammatory nature of the disease. Available for many years, Chlorpheniramine Maleate (CPM), is considered a low-cost and safe first-generation antihistamine displaying antiallergic, anti-inflammatory, and as of recently, identified as a broad-spectrum antiviral agent with activity against influenzas A/B viruses and SARS-CoV-2. Efforts have been made to identify repurposed drugs with favorable safety profiles that could significantly benefit the treatment of COVID-19-induced symptoms. The present case series highlights three patients in which a CPM-based throat spray was used to alleviate the symptoms of COVID-19-induced AVP. The CPM throat spray was associated with significant improvements in patient symptoms after approximately three days of use as opposed to the typical five to seven days reported elsewhere. While AVP is a self-limited syndrome and usually improves without pharmaceutical therapy, CPM throat spray may significantly reduce the overall time that the patient has symptoms. Additional clinical studies to evaluate the efficacy of CPM for the treatment of COVID-19-induced AVP are warranted.
摘要：
急性病毒性咽炎(AVP)是影响许多个体的常见呼吸道疾病。尽管对AVP进行了对症治疗，治疗缺乏针对广谱病毒和该疾病的炎症性质的治疗。可使用多年,马来酸氯苯那敏(CPM),被认为是一种低成本和安全的第一代抗组胺药，显示抗过敏，抗炎,最近，被鉴定为具有抗流感A/B病毒和SARS-CoV-2活性的广谱抗病毒剂。已经努力确定具有良好安全性的再利用药物，这些药物可以显著受益于COVID-19引起的症状的治疗。本病例系列重点介绍了三名患者，其中使用基于CPM的咽喉喷雾剂缓解了COVID-19诱发的AVP的症状。CPM咽喉喷雾剂与使用大约三天后患者症状的显着改善有关，而其他地方报道的典型五至七天。虽然AVP是一种自限性综合征，通常在没有药物治疗的情况下有所改善，CPM咽喉喷雾可显著减少患者出现症状的总时间。有必要进行其他临床研究，以评估CPM治疗COVID-19诱导的AVP的疗效。
